Tularaemia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Tularaemia - Pipeline Review, H1 2016', provides an overview of the Tularaemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tularaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Tularaemia - The report reviews pipeline therapeutics for Tularaemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Tularaemia therapeutics and enlists all their major and minor projects - The report assesses Tularaemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Tularaemia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Tularaemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tularaemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Tularaemia Overview 7 Therapeutics Development 8 Pipeline Products for Tularaemia - Overview 8 Pipeline Products for Tularaemia - Comparative Analysis 9 Tularaemia - Therapeutics under Development by Companies 10 Tularaemia - Therapeutics under Investigation by Universities/Institutes 11 Tularaemia - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Tularaemia - Products under Development by Companies 14 Tularaemia - Products under Investigation by Universities/Institutes 15 Tularaemia - Companies Involved in Therapeutics Development 16 Aradigm Corporation 16 Arno Therapeutics, Inc. 17 DynPort Vaccine Company LLC 18 Emergent BioSolutions Inc. 19 EpiVax, Inc. 20 Grifols, S.A. 21 Merck & Co., Inc. 22 Tetraphase Pharmaceuticals Inc. 23 Tularaemia - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 AR-12 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ARD-3100 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ARD-3150 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ciprofloxacin hydrochloride - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 EV-035 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 solithromycin - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 SRI-011225 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 TP-271 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 tularaemia [strain A] vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 tularaemia [strain B] vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 tularaemia vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 tularemia vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Tularaemia - Recent Pipeline Updates 55 Tularaemia - Dormant Projects 74 Tularaemia - Discontinued Products 75 Tularaemia - Product Development Milestones 76 Featured News & Press Releases 76 Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 76 May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 77 Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 77 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 79 Disclaimer 80
List of Tables
Number of Products under Development for Tularaemia, H1 2016 8 Number of Products under Development for Tularaemia - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Tularaemia - Pipeline by Aradigm Corporation, H1 2016 16 Tularaemia - Pipeline by Arno Therapeutics, Inc., H1 2016 17 Tularaemia - Pipeline by DynPort Vaccine Company LLC, H1 2016 18 Tularaemia - Pipeline by Emergent BioSolutions Inc., H1 2016 19 Tularaemia - Pipeline by EpiVax, Inc., H1 2016 20 Tularaemia - Pipeline by Grifols, S.A., H1 2016 21 Tularaemia - Pipeline by Merck & Co., Inc., H1 2016 22 Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Tularaemia Therapeutics - Recent Pipeline Updates, H1 2016 55 Tularaemia - Dormant Projects, H1 2016 74 Tularaemia - Discontinued Products, H1 2016 75
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.